OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
Albert Einstein College of Medicine · Thomas Jefferson University · +6 more institutions
Abstract
To assess the efficacy, safety, and tolerability of onabotulinumtoxinA (BOTOX) as headache prophylaxis in adults with chronic migraine.
Chronic migraine is a prevalent, disabling, and undertreated neurological disorder. Few preventive treatments have been investigated and none is specifically indicated for chronic migraine.
Citation impact
- FWCI
- 30.83
- Percentile
- 100%
- References
- 57
Authors
8- DWDavid W. DodickCorresponding
Albert Einstein College of Medicine, Thomas Jefferson University, University of California, Irvine, WinnMed, Swedish Medical Center, Mayo Clinic Hospital, Allergan (United States), Mayo Clinic in Florida
- CCCatherine C. Turkel
Albert Einstein College of Medicine, Thomas Jefferson University, University of California, Irvine, WinnMed, Swedish Medical Center, Allergan (United States), Mayo Clinic in Florida
- RERonald E. DeGryse
Albert Einstein College of Medicine, Thomas Jefferson University, University of California, Irvine, WinnMed, Swedish Medical Center, Allergan (United States), Mayo Clinic in Florida
- SKSheena K. Aurora
Albert Einstein College of Medicine, Thomas Jefferson University, University of California, Irvine, WinnMed, Swedish Medical Center, Allergan (United States), Mayo Clinic in Florida
- SDStephen D. Silberstein
Albert Einstein College of Medicine, Thomas Jefferson University, University of California, Irvine, WinnMed, Swedish Medical Center, Allergan (United States), Mayo Clinic in Florida
Topics & keywords
- Tolerability
- Medicine
- Migraine
- Chronic Migraine
- Placebo
- Clinical endpoint
- Clinical trial
- Randomized controlled trial